SPECIAL FEATURE – Parenteral Drug Delivery: Could a Dose of AI Improve Development?
By: Contributor Cindy H. Dubin
Elon Musk just warned the world that Artificial Intelligence (AI) is dangerous and has the potential to destroy civilization. Yet, AI will likely be used in nearly every industry, and the biopharma industry is no exception. A new report from VisionGain1 shows that 75% of pharmaceutical organizations want to use automated solutions more frequently, driven by injectable drug delivery. The report found that pharmaceutical production lines are challenged by customized dosages and products such as prefilled syringes (PFS). Therefore, manufacturers are searching for equipment that can handle the greater range of formats generated in smaller batch sizes, while still reducing downtime. Additionally, the popularity of injectables has increased the focus on sterility and product safety, an area where experts see AI having an impact.
While the industry is just at the precipice of discovering what AI can do for injectable delivery, this exclusive Drug Development & Delivery annual report highlights the strides that companies are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.
Over the past two years, more than $22 million have been invested in Aenova’s Latina site to offer customers modern, Annex 1-compliant, aseptic filling technology for sterile dosage forms, especially vials and PFS. This new manufacturing area has been approved by the Italian authority (AIFA). Follow-on investments of approximately $16 million are currently underway to further expand the offering.
“The prefilled syringes segment is indeed increasing for the usage of controlled drug delivery devices on targeted therapies, such as monoclonal antibodies and cell and gene therapies,” says Paolo Abbate, Managing Director, Aenova Latina Site. “Moreover, the request is always combined with a need for high dosage accuracy. Aenova, a CDMO, can offer a high performance line with ±1% dosage accuracy.”
The Latina site also features a visual inspection system to assure that the product delivered to the patient is of the highest quality and that defects are minimized. “Fully automated filling lines under Restricted Access Barrier Systems (RABS), or Isolation, significantly reduce the risk of both breakages and contamination,” he says. “Aenova is currently performing extensive assessment of the packaging equipment on the market to ensure that we remain at the forefront of technology to further reduce secondary and tertiary packaging defects.”
The Aenova Site Latina offers manufacturing services to a global market for both clinical trials material manufacturing and commercial supply.
A new filling line can support batches from 10L to 1,500L, working with both disposable and stainless steel equipment trains. “Technology transfer activities and the PPQ strategy are established in agreement with customers and are fully compliant with cGMP guidelines,” says Mr. Abbate. And quality control supports in-process control, product release, and stability testing, while also providing a comprehensive service for microbiological and chemical testing.
Ajinomoto Bio-Pharma Services is a CDMO with six automated aseptic fill lines that have the capability to fill early-clinical through commercial products in vials, syringes, and cartridges. With the increase in demand for biologics in the market, Aji Bio-Pharma has technical experts with the experience to meet the unique needs of these products. “We also pride ourselves on being one of the few CDMOs with complex formulation expertise that includes a strong formulation team with extensive knowledge to help guide clients when manufacturing lipid nanoparticle (LNP) products,” says Jennifer Etchison, Sr. Director of Business Development, Aji Bio-Pharma US.
As a mid-sized CDMO, Aji Bio-Pharma is flexible to cater to all product life-cycle phases. “For early-phase projects, we have capabilities to fill small batch sizes and manufacturing slots for quick turnaround times,” she explains. “For late-phase/commercial projects, we have high-speed lines to accommodate larger batch sizes, scale-up, Process Performance Qualification protocol, and commercial experience.”
In response to customer requests to increase batch size capabilities and accommodate larger commercial batches, Aji Bio-Pharma’s San Diego site expanded aseptic filling capacity with a new high- speed multi-purpose filling line. This line is fully contained within an isolator and offers a range of configurations, including prefilled syringes, cartridges, and vials, and utilizes ready-to-use components to provide component and scheduling flexibility. And, to accelerate batch release and get client products to market sooner, the company has invested in automated and semi-automated visual inspection equipment.
ApiJect helps pharma companies improve delivery of liquid pharmaceuticals in customized, efficient, and scalable prefilled drug delivery systems. The ApiJect platform is a device design and manufacturing process that brings together the scale and economics of Blow-Fill-Seal (BFS) aseptic filling with the simplicity of attachable plastic component design, such as needle hubs, to create simple, prefilled injectors. Additionally, ApiJect devices can be designed with safety features, such as needle shields and auto-disable mechanisms, as well as single-dose packaging.
“Whether it is a high-value injectable treatment for a small number of patients or an essential vaccine for the world, ApiJect helps pharma companies deliver more of their injectables to the patients who need them,” says Tony Wasilewski, MPD2, PMP, Vice President, Pharmaceutical Development Services, ApiJect Systems.
He explains BFS is more compact and requires fewer raw materials than traditional glass filling lines or traditional prefilled syringes. This, he says, has become a key factor as companies consider supply chain shortages. “Rather than glass, we embrace pharmaceutical-grade resin to create almost our entire device, with the exception of the hypodermic needle,” says Mr. Wasilewski. “Better control over the materials, a less complex supply chain, and the use of resin instead of glass allow devices packaged in BFS to reduce or eliminate many of the hazards that can lead to product recalls from packaging.”
While ApiJect drug delivery systems are still in development and have not been cleared by the FDA or other regulators, ApiJect is working with several pharma partners to develop ApiJect prefilled injectors for their injectables. He says: “The potential of our platform is what led to our development agreement with global contract manufacturer, Fareva. With the support of the French Government, Fareva is building three new BFS lines in France with ApiJect technology to fill-finish vaccines in ApiJect prefilled injectors.”
Sensitive drugs and biologics require additional protection from filling to the point of administration. Choosing the right primary packaging for these drugs is critical, and manufacturers must ensure that their syringe and components protect the drugs without compromising on key functional performance such as gliding force, break-loose force, container closure integrity, and machinability.
Ethylene Tetrafluoroethylene (ETFE) film-coated closure components are now commonly used for packaging sensitive vaccines and biologics. “ETFE film-coating possesses excellent chemical resistance and has been proven to act as a barrier that protects the drug from extractables and leachables and the potential threat they present to the integrity of the drug formulation,” says Audrey Chardonnet, Director of Business Development for Prefilled Syringe Components, Aptar Pharma.
While ETFE film-coated components are an effective solution for packaging sensitive drugs, they are not without their challenges. To date, compatibility with vent tube filling methods and achieving consistent functional performances remain key unmet needs when using ETFE-coated syringe plungers, she says. As a result, Aptar Pharma has developed new designs of coated syringe plunger to promote machinability, container closure integrity, and functional performances.
Aptar Pharma uses a proprietary 3-rib design for its ETFE-coated solution, PremiumCoat®, with the trim rib specifically positioned to avoid interference with functionality. Because the three ribs come in contact with the glass, compared to the market standards, PremiumCoat has demonstrated its capacity to preserve container closure integrity, even in deep-cold storage conditions. This design was also shown to enable low and consistent gliding and break-loose forces, which facilitates the development of autoinjectors. Aptar Pharma also performed a series of machinability testing to demonstrate that PremiumCoat is compatible with vacuum and high-speed vent tube filling lines.
“With Aptar Pharma’s 3-rib PremiumCoat design, manufacturers can reconcile ETFE coating with machinability, container closure integrity, and functional performance, providing superior protection for sensitive drugs, optimizing operations on their filling lines, and ensuring safety for their patients,” says Ms. Chardonnet.
Pharma companies developing new injectable medicines are aiming to meet more patient needs. This is evident with the development of new off-the-shelf autoinjectors that can administer larger volumes of drug product (eg, 5mL). To meet this demand, CDMOs such as Catalent are adding more high-speed, state-of-the-art assembly solutions, which are able to accommodate these innovative devices.
Catalent Biologics’ drug product facilities in North America and Europe provide integrated solutions for customers developing new biological entities, biosimilars, and sterile injectables. These include early-phase development and manufacturing to late-phase commercial fill-finish and packaging.
“We work to simplify the tech transfer of products between the company’s early phase facilities and late-phase/commercial facilities, which reduces risk, and accelerates programs through the clinic and to market,” says Brian Galliher, Principal, Process Engineer, Catalent Biologics.
“Robust tech transfer processes also help to ensure that risks are minimized, and equipment selection is critical (e.g., single use system compatibility, filling and packaging/assembly equipment) along with thorough qualification programs such as line handling studies, engineering runs, container closure studies with container closure integrity testing (CCIT).”
Catalent continues to see growth in the prefilled syringe market. COVID-19 vaccines, for example, are moving away from the multi-dose vials and into single-dose syringes (and single-dose vials), and new treatments to reduce obesity are focused on at-home patient administration. These are following the trend to include prefilled syringes and autoinjectors for both the ease of use and patient adherence reasons, says Mr. Galliher.
A customer of Catalent initially launched its product in a 1mL-long syringe, which required the patient to administer two doses for one treatment, and was not the ideal situation. In parallel, Catalent qualified a 2.25mL format in primary and secondary packaging, including an autoinjector assembly. For the patient, this new format has the potential to reduce the number of injections per treatment, and the use of an autoinjector provides benefits of ease of use and safety.
Congruence: Autoinjector Could Mitigate Premature Removal
Several trends are driving the need to inject high-dose biologics into the subcutaneous (SC) tissue. But high viscosity (25-150+cP) and higher injection volumes associated with high-dose drugs challenge the limits of what is feasible with legacy spring-powered autoinjectors due to high injection forces required.
“Tradeoffs are imminent when accepting spring-powered autoinjector size for high-dose biologics either by needing to use a large device and/or long injection times, both of which impact patient experience and comfort,” says Gautam Shetty, PhD, Congruence. “Designing an autoinjector for high-dose drugs is not simply a scaling problem (ie., making existing autoinjectors bigger). Hence, alternate – compact yet powerful – energy sources in an autoinjector or new technology platforms, such as wearable injectors, are being pursued.”
He adds that administering high-dose drugs with conventional spring-based autoinjectors is limited by low flow rate and long injection times because of insufficient force for faster delivery. There is a risk that cold temperature, when the drug viscosity is even higher, could render the autoinjector incapable of injecting, which would result in a missed or lost dose. Therefore, an autoinjector should provide sufficient force to operate even when an injection is attempted immediately after removal from a refrigerator.
Even though autoinjectors have been widely used, usability shortcomings have always existed. One such example is premature removal of the autoinjector prior to dose completion.
“Congruence user studies and published literature indicate that pushing the autoinjector against the injection site and holding it for an extended time is not obvious,” says Dr. Shetty. “This problem is amplified with high-dose biologics, which would need longer injection times. User fatigue, exacerbated by longer injection times, could also cause premature removal of an autoinjector from the injection site.”
Current autoinjector designs do not provide a safety net against premature removal. Once injection is initiated, current autoinjectors continue to dispense the drug even if the autoinjector is prematurely removed from the injection site, claims Dr. Shetty. And the safety shield locks, preventing the patient from resuming the injection. This results in an incomplete dose and potential non-compliance with therapy.
Another important consideration is that the pipeline of high-dose biologics includes patient populations with no history of self-administration using an autoinjector, such as patients with non-chronic conditions. Therefore, traditional risk mitigation strategies could potentially be irrelevant, says Dr. Shetty.
“The Congruence High Dose Autoinjector addresses high injection force need by incorporating a compressed gas source and addresses the usability issue of premature removal from the injection site by offering an Injection Pause™ feature,” says Dr. Shetty. “This feature ensures that the injection is paused, should the autoinjector be inadvertently (or deliberately) removed from the injection site.”
Growth in the demand for dual-chamber prefilled syringes is being driven by multiple factors in the injectable pharmaceutical market. The delivery of medications is rapidly moving outside of the formal healthcare system and injections are being performed by more naïve users. The complexity of injectable drug products is growing, requiring separation of drug components during storage, despite efforts to achieve liquid-stable formulation. Pharmaceutical manufacturers are looking to drive cost and time efficiencies in their development pathways. Regulatory authorities desire clinical trials to be performed in the delivery system that will be used commercially. Emerging biotechs seek greater value by developing their novel therapies in enabling delivery systems.
“These factors have created pent-up demand for a user-friendly, effective, and safe delivery system for those drug products that require separation during storage,” says John Merhige, Chief Commercial Officer, Credence MedSystems, Inc.
To satisfy this need, advances in technology are emerging both in the development of dual-chamber delivery systems as well as in the fill-finish processing of those devices. “It is not surprising that collaboration between device manufacturers and drug manufacturers is required to unlock the full potential of dual-chamber systems, the quintessential example of a drug-device combination product,” he adds.
Credence MedSystems is developing its family of Dual Chamber Syringe products to meet the varied needs of these applications. The platform’s flexibility is highlighted by the ability to turn any conventional barrel into a dual-chamber system that can allow either reconstitution or sequential delivery. In the area of reconstitution, the liquid can be mixed with a powder, lyophilized cake or another liquid before the reconstituted solution is injected. In sequential delivery, the two liquids are not mixed, but rather injected in sequence with one push of the plunger rod. Both configurations are available either with a needleless luer lock front end or with Credence’s proprietary integrated needle-retraction technology.
“The passive needle retraction reduces the likelihood of needlestick injury, while integrating the needle-safety mechanism into the prefilled syringe eliminates capital and operating expense associated with conventional add-on safety devices,” says Mr. Merhige. “Credence’s Dual Chamber Syringes have fared extremely favorably in human factors evaluations as ‘stand-alone’ syringes, but can also be employed in conjunction with disposable or reusable autoinjectors.”
One of Credence’s collaboration partners advancing dual-chamber filling is Bryllan, LLC, a contract manufacturer of complex and novel drug products. Bryllan’s existing filling capabilities, along with its plans for expansion, provide pharma innovative solutions in the manufacturing of ready-to-use systems, including dual-chamber syringes and bags. “With the ability to handle potent, toxic, and sensitive products, experience in both liquid and powder filling, and the expertise to build and operate highly flexible filling suites, Bryllan’s advances are facilitating adoption for this field of drug delivery,” Mr. Merhige says.
He adds that when paired with enabling fill-finish capabilities, Credence’s Dual Chamber Syringes simplify administration of challenging drugs; reduce risks in the areas of accidental needlestick, dosing errors, contamination, and exposure to potent substances; and address economic factors by decreasing drug overfill and time of administration. He concludes: “These technological advances are addressing the trends in the market and providing value to patients, healthcare providers, and pharmaceutical manufacturers.”
DALI Medical: Bringing Down the Cost of Integrated Safety Features
DALI Medical Devices offers a range of patient-centric injectable drug delivery devices that meet the need for enhanced safety and ease-of-use, both for clinical trials and commercial drugs. The company also provides complete injectable drug delivery device development solutions that are customized for specific requirements relating to drug properties and user preferences, handling everything from concept to commercialization. DALI’s portfolio offers solutions for liquid injectable drugs, drugs that need to be reconstituted, vials, prefilled syringes, etc.
Injectable drug delivery devices with integrated safety features do present various development and manufacturing challenges, often leading to higher costs compared to basic needles and syringes, explains Ziv Cahani, Vice President, Business Development, DALI. However, there are various strategies that can be implemented to simplify the manufacturing processes and supply chain, and bring down costs.
For example, DALI Medical offers safety needles and safety syringes that provide passive protection against needle stick injuries. With these devices, the safety features are activated automatically, without the user having to do anything.
“Although it’s logical that the more advanced devices would be more costly to produce, strategies such as design-to-cost and design-to-manufacturability can make a huge difference in manufacturing costs,” says Mr. Cahani. “By working closely with experts in injection molding, assembly automation, and raw materials selection, it is possible to offer highly advanced solutions with affordable pricing.”
He recalls that one of DALI’s customers was looking for a safety-enhanced delivery device for a super-high-viscosity drug. “We developed a version of our SAN®-Light passive safety needle, customizing it to meet the viscosity challenges and other requirements, including regulatory requirements and user preferences. The customized safety needle is tuned to the viscosity properties of the drug, provides a high level of safety, and incorporates features aimed at minimizing needle phobia anxiety as well as real and/or perceived pain.”
Datwyler: Proprietary Coating Reduces Particulates
Datwyler’s experience in rubber components has led to the development of NeoFlex™ plungers, a coated solution for prefilled syringes and cartridge-based delivery systems. Datwyler’s proprietary spray coating technology provides a protective barrier to external contaminants, prohibiting leachables from entering the product and ensuring a contact-safe surface that is compatible with the drug, explains Paolo Ferrigno, Product Manager, Prefilled Syringes and Cartridges, Datwyler. “With our proprietary fluoropolymer coating technology and lack of need for silicone lubrication (under specific conditions), Datwyler contributes to a reduction in overall visible and subvisible particles.”
The NeoFlex plunger production process is flexible to support the development of new products to optimize design according to customers’ requirements and future life cycle management. “NeoFlex plungers have proven functionality in many plastic barrels, which are becoming more frequently requested for large containers to mitigate increased glass breakage risk,” Mr. Ferrigno says.
Large-volume NeoFlex plungers are designed for self-injection devices. The increasing interest around self-injection devices has led to the development of solutions aimed at improving patient wellness and safety, the self-administration experience, and total cost reduction for authorities. The availability of new technologies and smart connection features allows for remote monitoring and reduces the risk of improper administration, incorrect dosage, and poor compliance.
In a PFS, a rubber closure is required to maintain sterility and needle integrity. For autoinjectors, a Rigid Needle Shield (RNS) seals the system, preventing contamination and preserving the sterility. The external plastic (polypropylene) shield is used to improve the mechanical interface with the autoinjector, allowing for a safer removal and eliminating the risk of tears or fails.
“For use in delivery systems, the functionality of the RNS needs to be proven both with the primary container (the syringe) and with the autoinjector,” he says.
Datwyler provides RNS solutions in two sizes (1/2” and 5/8”), suitable for use in subcutaneous and intramuscular parenteral administration. “There is a clear trend to move from IV to subcutaneous/intramuscular administration, resulting in the development of large-volume delivery devices,” says Mr. Ferrigno.
Datwyler’s FM30 rubber compound is designed to allow ETO gas to penetrate, sterilize, and evacuate, while maintaining a low oxygen and water vapor transmission rate, Mr. Ferrigno explains. Different levels of siliconization are available to accommodate the pull-off force for a variety of syringe types.
Leveraging 20-plus years of CDMO experience, and having supported manufacturing activities for more than 200 molecules, INCOG was designed and built as a new 90,000-sq-ft facility to support drug product fill-finish manufacturing for biopharma companies. The facility is cGMP production ready, and is actively manufacturing commercial PPQ batches. There are currently 40 million units of installed annual capacity to fill vials, syringes or cartridges with an expansion in 2024 that will take capacity to over 140 million units per year. INCOG also offers services and support in development, QC, inspection/labeling/packaging, device assembly, stability studies, and storage.
INCOG was introduced to a biopharma company that was previously using a Tier 1 CDMO in the US to manufacture a commercially approved prefilled syringe. Cory Lewis, CEO, President, & Founder of INCOG, explains that this company shared its frustration with the customer experience it had been receiving from its existing CDMO.
“They experienced poor communication, delayed responses, and a lack of proactive updates related to the manufacturing of their commercial program that resulted in manufacturing challenges, low yield results, and excessive rejection rates from batches,” he says. “The improvements that we offered to our customer included an unparalleled customer experience from contracting to technical transfer to batch manufacturing, as well as manufacturing benefits resulting in improved yield via line setup, and the 100% in-process weight checks integrated throughout the filling process.”
Mr. Lewis adds that the customer was invited to INCOG to utilize the person-in-plant offices, demonstrating a commitment to the partnership. INCOG has begun manufacturing the PPQ batches and expects to host the FDA for the pre-approval inspection by early 2024.
“Our commitment to being customer-driven is what sets us apart from other CDMOs and gave our biopharma customer the confidence they needed to trust our company with their commercial prefilled syringe project,” he says.
With a focus on PFS, Mr. Lewis says that while he sees a limited market presence of devices with integrated safety features, he believes that the industry will continue to respond to this challenge by leveraging emerging technologies and process innovations to streamline and optimize the manufacturing process. “Additionally, I expect that regulatory agencies will continue to drive demand for these products, placing increasing pressure on manufacturers to deliver safer and more reliable drug delivery solutions,” he says.
He also sees industry taking action to address issues of breakages, leachability, defects in packaging, and contamination. “There will be a greater emphasis on design and engineering to ensure that prefilled syringes are robust, durable, and resistant to breakages and defects,” he says. “There also will be a continued focus on materials science to identify and mitigate leachability and contamination risks. Finally, quality control and supply chain management will be improved to ensure that packaging defects are identified and addressed before products reach the market.”
Lifecore Biomedical is a fully integrated CDMO offering expertise in complex aseptic formulation, aseptic filling into syringes and vials, and final packaging of injectable drugs and medical devices. Lifecore also manufactures pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) through a proprietary fermentation-based process.
Some of Lifecore’s clients require high-gauge cannulas and needles for precision use in ophthalmic surgeries. “Due to high-viscosity formulations, injection pressure can increase the risk for needle detachment at the luer,” says Kipling Thacker, PhD, Vice President & Chief Scientist at Lifecore. “In these cases, we have worked with our clients to implement needle-retention devices designed to prevent needle separation.”
Ophthalmic drug and device manufacturers also need to comply with USP <789>, which defines testing parameters for particulates in solution. Dr. Thacker says the key to meeting the USP requirements is to avoid issues with particulates in all phases of production. “To address this issue, we have partnered with ready-to-use vendors on measures, such as the use of alternative syringe and vial materials, syringe cleaning, and improved component packaging. While the value of testing remains, asking the right questions up front and using a Quality-by-Design approach during development helps ensure a safe, consistent drug supply for patients.”
Lubrizol Life Science – Health (LLS Health), CDMO Division, meets client demand for clinical trial material packaged in prefilled syringes by utilizing its Colanar Model FSM 1033. In this tub-based system, Lubrizol can fill PFS, cartridges, and essentially any primary packaging that fits in a tub, says Brett Braker, Engineering Supervisor, Technical Operations, LLS Health.
“This equipment offers us a lot of flexibility to help our clients,” he says. “Presently, we can fill 1-10mL syringes, but custom requests are feasible, and the system is particularly useful to fill smaller batch sizes that our clients seek. Larger, less flexible CDMOs, aren’t willing to break into their productions to accommodate these requests. We, however, do not have a minimum batch size while having the capability to manufacture both aseptically processed and terminally sterilized material.”
The consistency of filling accuracy and the bubble size in the cartridge helps reduce waste, which is important when working with high-value biologics and complex suspensions and emulsions. The filler operates using servo drives and a built-in peristaltic pump and bubble sizes are controlled using vacuum stoppering.
Most of the work LLS Health performs is for pharmaceutical clients seeking to increase the solubility and bioavailability of insoluble APIs or to improve long-acting drug products via the 505(b)(2) route. Recently, a large wearable device manufacturer asked the CDMO to perform some pre-clinical and clinical device validation work.
“When many larger, less flexible organizations had actually turned this client away, we leveraged the Colanar Model FSM 1033,” explains Mr. Braker. “Working closely with the company, we provided both filled cartridges and fully assembled wearable devices. We made a range of material from 1 to 100 cP, helping them to define the limitations of their device for validation. Ultimately, we made both R&D and aseptically filled cartridges for clinical use.”
Mr. Braker says this partnership was a win-win for both companies. “Through helping the device manufacturer with their work, we learned more about our equipment, honing our ability to control the bubble size in the primary packaging, for example.”
He adds that wearable devices, such as the one this client was developing, help patients maintain a more consistent level of the API in the blood. He says: “Wearable devices help with patient compliance and comfort as the devices often come prefilled, allowing them to dose themselves at home.”
Mitsubishi Gas Company provides multilayer plastic vials, OXYCAPT, for the pharmaceutical industry. These products are often suited for biologics and cell and gene therapies stored at low or ultralow temperature. Plastic primary containers are expected to grow in popularity as companies consider storage for advanced drugs.
“As the compositions of advanced parenteral drugs have become more complex than existing drugs, we believe special and appropriate primary containers are required,” says Tomohiro Suzuki, Associate General Manager, Mitsubishi Gas Chemical Company. “Special features, such as high pH resistance, low extractables, low protein adsorption, high break resistance at ultralow temperature, high oxygen barrier, high ultraviolet barrier, etc., are necessary for primary containers used for advanced drugs.” He adds that multilayer plastic vials and syringes overcome breakage and leachability common with glass containers.
Mitsubishi Gas Chemical Company signed a Letter of Intent with Becton Dickinson (BD) in May 2022 and has started earnest discussions to apply its multilayer technology to next-generation PFS for biologics. “We believe this collaboration will be helpful for the pharmaceutical company to safely develop novel and sensitive future drugs,” he says.
Nemera offers a range of parenteral devices to support pharma companies’ combination products sprint to market. For example, the on-body injector platform, Symbioze®, administers complex, large-volume drugs, such as monoclonal antibodies, with an adjustable flowrate. The sustainable device features a reusable electronic part and disposable module. “Technically, Symbioze is a complex device, yet it offers simplicity without overcomplicating user steps nor compromising patients’ experience,” says Cecile Gross, Global Category Manager Parenteral, Nemera. The main innovation lies in keeping the sterility between the two modules, ensuring patient’s safety.
To avoid breakages, alternatives to glass prefilled syringes are on the market today, such as plastic-based syringe (COP). PFS manufacturers are also working on reducing silicon tungsten residues to prevent undesirable reactions between drug formulation and devices. “Our premium passive safety device add-on for prefilled syringes, Safe’n’Sound®, a passive safety device, highly customizable, available in 1mL and 2.25mL, is compatible with ISO glass syringes and 1mL COP PLAJEX™ syringe,” says Ms. Gross.
She continues: “We offer continuous holistic support, including assembly equipment implementations to avoid breakage and other defects during manufacturing processes, optimizing the line’s adaptation for our device to avoid recalls.”
A Safe’n’Sound and Terumo PLAJEX 1mL-long prefillable syringe combination product has been launched in several markets for biosimilar administration to treat chronic inflammatory diseases. Ms. Gross says: “Thanks to our regulatory expertise, we helped our customer navigate the complex regulatory landscape to file specific combination product dossier registration in USA, Europe, and Japan.”
Nemera also offers reusable and disposable pen injector platforms, including PenDura, PenOne, PenVario, and PenHV to treat diabetes, obesity, hormone imbalance, and osteoporosis among others, and are all ergonomic user friendly.
Novocol Pharma: Simplifying Lyo With a Cartridge-Based Reconstitution Solution
Novocol Pharma is a CDMO specializing in sterile cartridge fill-finish, supporting clinical-phase and commercial customers with turnkey services from product development to final device assembly. Through its device division, Duoject Medical Systems, Novocol offers drug delivery design services and solutions, including a portfolio of reconstitution, injection, and safety systems.
According to Eric Lee, Business Development Director, Novocol Pharma, the company is well-positioned in fill-finish of cartridge-based injectable products, a key format in autoinjector, pen injector, and wearables-based delivery platforms, and offers device assembly capabilities for cartridge-based pen injectors with equipment compatible with pen injector devices from leading global suppliers.
In addition, solutions from Duoject align with the growing trend of patient-centric drug delivery systems. “As the demand for self-administration continues to grow, there is an emphasis on safety features to reduce needlestick injuries,” he says. Such solutions include the Falcon safety device, a prefilled syringe safety system, and PenPrep EVO, a cartridge-based reconstitution system, which both prevent needle exposure during patient use.
Novocol offers a complete solution to the challenges presented by drug reconstitution, particularly the multi-step process with the PenPrep EVO device and in-house sterile cartridge filling services. This allows users to reconstitute a lyophilized drug product vial with a diluent cartridge. Once reconstituted, the mixture is drawn back into the cartridge for self-administration use with cartridge-based pen injectors.
Mr. Lee explains that a notable example of this turnkey offering includes a recent product lifecycle management project for a commercially marketed drug product in vial format that was only stable in lyophilized form. The application required patient self-administration several times a week using multiple vials, syringes, and needles. “By introducing the PenPrep EVO reconstitution device, a diluent cartridge that was developed and produced at Novocol, and a commercially available pen injector, the patient experience for the drug product was greatly enhanced, resulting in several improvements,” he says. This includes replacing and simplifying multiple components and processing steps using one reconstitution device (containing both the drug vial and diluent cartridge), and pen injector device for self-administration. Another benefit is improved patient safety and eliminated risk of needlestick injury during the drug reconstitution process though PenPrep’s needle safety feature.
Noxilizer: NO2 Sterlization Maintains Drug Integrity
Noxilizer offers pharmaceutical, biotech, and medical device companies an ultra-low temperature sterilization process. Nitrogen dioxide (NO2) sterilization is an alternative to ethylene oxide (EO) and hydrogen peroxide (VHP). NO2 sterilization can operate between 10°C-30°C, offers minimum vacuum pressure, and performs surface sterilization with little to no residuals while maintaining drug integrity.
Maura O. Kahn, Senior Vice President, Commercial, Noxilizer, recounts how one global biotech company product team was evaluating multiple syringe types and sterilization methods, including EO and NO2. Noxilizer staff became part of the product development team, conducting feasibility studies to assess the syringe brands and designs, vacuum budget, lethality cycles to confirm the most challenging location and initial cycle parameters, and ingress and external residuals. The biotech company identified a syringe design candidate that reduced risk to the product during the manufacturing process. Testing determined that only NO2 sterilization worked with this syringe design. Since 2019, the company has executed a number of sterilization studies with their product and packaging. They have completed sterilization validation at two locations. This product will be submitted for regulatory approval in 2023 and commercial product is expected in 2024.
Ms. Kahn explains that, for pharmaceutical and biotech companies with large product portfolios in one therapeutic area, developing a standard delivery device and sterilization method will accelerate product development and time to market. As an example, she says that Noxilizer has worked with a global biotech company for more than four years as the company evaluated a number of syringe designs and sterilization methods, including EO, VHP, Peracetic Acid, and NO2. She recalls that initial testing showed that only EO and NO2 could achieve lethality in the most challenging location in the various syringe designs. Therefore, further testing was done to assess the pros and cons of both EO and NO2. Extensive testing includes evaluating product and water-filled syringes that have been exposed to worst-case NO2 cycle conditions – accelerated and real-time testing over 24 months. In both cases, product and water-filled syringes showed minimal to no NO₂ (or nitrates) ingress into the syringe contents. Drug integrity was maintained.
She says: “This, along with the other benefits of ultra-low sterilization, minimal vacuum, and short total process time when compared to EO, has led the company to select NO2 sterilization for all products in development within this therapeutic area.”
One World DMG designs and manufactures injection trainers and patient onboarding materials for the pharmaceutical and biopharmaceutical industries to ensure patient adherence and better health outcomes.
“The importance of helping patients as they begin their self-injection treatment is widely understood by the healthcare community,” says Paul Randall, Vice President, One World DMG. “Successful training programs support the patient by educating, building confidence, and partnering with them throughout their health journey.”
One World DMG works with patient educators and healthcare providers to gather insight into the needs of patients and their real-world experiences. Heidi Holden, Registered Dietician and Certified Diabetes Educator, shares her thoughts on the discrepancies in training experiences for patients: “I have different feelings about patient training in the office. There are several factors involved. For example, how well was a nurse trained on that device? When was the last time they themselves trained on that device? How much time do they have to train the patient? Often, they really don’t have the time to explain to the patient why they’re taking the medication, what it does, so that’s a problem.”
“The transition from training in the HCP office exclusively to distributing trainers to patients has been adapted by One World DMG’s long-term clients who see the benefits re-usable injection trainers provide in the home setting,” says Jonathan Coe, Regional Director, One World DMG. The benefits to the manufacturer are also evident in the example of a client who felt they had a design concern with their autoinjector that needed to be addressed. Using the One World’s trainer for their autoinjector in human factors testing revealed a much less complicated issue that could be addressed thereby avoiding hefty and unnecessary expenses.
In addition to injection trainers, One World DMG’s onboarding offerings include: patient starter kits, HCP injection demonstration kits, injection trainer packaging, instructions for use, quick reference guides, training videos and animations, as well as injection demonstration models – all designed to enrich the patient experience and overall safety.
“Manufacturers are putting more emphasis on safety in onboarding patients and training HCPs,” says Diane Ranshous, Regional Director, One World DMG. “Injection trainers play a key role in improving patient safety. The ability to repeatedly practice the injection process with a safe “replication needle” familiarizes the patient with the product and the steps necessary to better ensure their protection. And while the technology will continue to develop, the need for strong training tools and educational support remains a critical component for both patients and HCPs.”
UniSafe® from Owen Mumford Pharmaceutical Services offers pharmaceutical companies the benefit of a spring-free safety device with a choice of 1mL and 2.25mL prefilled syringes. The absence of a spring provides ease of use and offers the patient an unobscured view of the syringe contents to check dose and clarity. In addition, there is no risk of pre-activation during transport and before use. UniSafe’s design also features a secure integrated plunger that helps prevent removal and accidental drug spillage, and provides tamper evidence. The design also creates a device that has a simple final assembly.
“With the growing market in biologics and doses increasingly more than 1mL, UniSafe 2.25 provides a device for formulations with larger fill volumes,” says Michael Earl, Director of Pharmaceutical Services at Owen Mumford. “UniSafe’s design means that the operator can use the same technique as a typical syringe when administering medication.”
In the US and Europe, regulations require needle-shielding devices to protect from needlestick injuries. Ideally, the needle protection should be integral to the device and require no additional user steps before and after use. UniSafe syringes feature a spring-free safety design with passive needle shielding that is employed as the user fully depresses the syringe plunger using the usual technique.
Mr. Earl shares that a key market driver influencing device design for parenteral administration is the need for more sustainable products. This includes raw materials (often plastic) as well as the manufacturing processes and transportation across the supply chain. Product packaging will also need to meet environmental standards, as changes in EU packaging regulations require all packaging to reach targets for recycling by specified dates.
“Designs that enable reduction, reuse or recycling are key methods to help achieve reduction in harmful emissions,” he says.
Another trend is the addition of connectivity and data exchange to delivery devices, which help patients self-administer medication in their home setting and be less dependent on healthcare professionals (HCP). Data transferred from connected devices can confirm medication delivery, date, and time as well as help HCPs monitor patient compliance to their therapy and provide the necessary interventions to improve patient outcomes.
PCI is a global CDMO that provides integrated end-to-end drug development, manufacturing, and packaging solutions to increase product speed to market. “Our clients aim to accelerate their sterile drug development lifecycle and seek readily available capacity, reducing time to clinic and ultimately commercial launch,” says Shawn Cain, Senior Vice President Development and Manufacturing, PCI. “PCI plays a key role in navigating development complexities and overcoming manufacturing and packaging challenges posed by both drug products and drug delivery devices.”
PCI offers a full suite of sterile injectable drug development and manufacturing services, including formulation development, aseptic fill-finish of vials, bottles and prefilled syringes, and lyophilization, complete with dedicated in-house QC analytical and microbiological support. Complementing its core sterile manufacturing and filling solutions, PCI offers assembly, packaging, and labeling of advanced injectables such as prefilled syringes, syringes with needle safety devices, autoinjectors, and pens.
“Combining our expertise in sterile fill-finish manufacturing with specialist biologic packaging, labeling, and cold chain distribution provides a valuable end-to-end solution, simplifying the supply chain while delivering time and cost efficiencies,” says Mr. Cain.
Just as fast-tracking product to market is important so too is the fact that the pandemic fast tracked acceptance of self-injection, opening opportunities for new medicines and further improvements of drug delivery devices. “The growth in medical devices, be it needle safety devices for prefilled syringes or autoinjectors, pens and wearables platforms, has allowed the industry to take a significant step forward for standardization and for improving the patient experience,” says Justin Schroeder, Global Vice President Technical Sales, PCI. “Likewise, these new pathways allow for administration of the growing number of biologic medicines that can be truly life-changing for patients.”
Safety is at the core of self-administration. Both the economics and the manufacturing technologies have progressed to make needle safety a standard. “We continue to see that where sponsor companies develop advanced delivery forms such as an autoinjector, there is absolutely a consideration for a PFS-NSD (needle safety device) as an interim lifecycle solution or as a complementary option to the autoinjector platform to serve all markets and pathways for administration,” explains Mr. Schroeder. “In addition, where clinical trials had traditionally been executed in vial format, and PFS platforms were more of a commercial stage drug delivery solution, we are now seeing more sponsor companies integrating PFS-NSD (and AI) into their clinical trials. This can provide multiple benefits, including more patient-friendly drug delivery, improved patient retention in trials, shortening duration of the trials, and more impactful study data. These factors are of significant benefit for filing and regulatory approval acceleration. I believe in less than 5 years it will be uncommon to find a PFS that does not offer some type of needle safety mechanism.”
It is also quite common to select packaging materials during the drug development process to ensure product compatibility and to identify potential for product contamination that could affect product stability or efficacy. In parallel, physical testing of the PFS and assembled pen or autoinjector is critical.
PCI’s European sterile fill-finish facility in Leon, Spain, entered into an agreement with a mid-sized biopharmaceutical company that was looking for a technology transfer of their oncology prefilled syringe product. Mr. Cain explains that the project began with the program in early development; it was a complex subcutaneous injection in suspension product with a challenging step of sieving during suspension compounding. The challenge was that this sieving step was to be performed under aseptic conditions, as the product suspension could not be terminally sterile filtered. At the point of project initiation, the client had only performed this process under non-aseptic conditions. PCI process engineers worked to scale up the batch and optimize the process of sieving by redesigning the formulation process. This was accomplished by modifying the equipment and processing components to execute the sieving process in both a GMP and aseptic manner. Initially, the sieving process did not work at the commercial scale, so PCI initiated a Design of Experiments (DoE) program to explore other alternatives to the sieving step without impacting the CQAs or CPPs of the drug product. “After multiple DoEs and stability studies, we successfully developed a more robust scalable process with positive stability results and sterility assurance,” says Mr. Cain. “This project has now progressed to registration batches pending FDA regulatory review for US market supply.”
Recipharm delivers design, development, manufacture, and sterile fill-finish of injectable drug products. This includes autoinjectors, blow-fill-seal, prefilled syringes and cartridges, vials, and ampoules. The company handles various formulations, including liquids, lyophilized, and dry powders.
Recipharm has a partnership with Sensyo Pharmatech for injectable manufacturing in Morocco and has a development center in Solna, Sweden, which develops formulations for multiple routes of administration. In addition, a device center in King’s Lynn, UK, offers full flexibility to parenteral drug developers with the proprietary VapourSoft®-powered injection devices, capable of delivering high-viscosity formulations. VapourSoft is a compact energy source using liquefied gas, rather than a spring. Through gentle release of a pressurized vapor, the device powers viscous drug delivery through a fine needle with minimal user effort. “This technology can enable the self-administration of formulations with viscosities of up to thousands of cP using relatively fine needles to improve patient comfort,” says Louise Righton, Head of Strategic Marketing – Advanced Delivery Systems, Recipharm.
VapourSoft-powered devices can be tailored to the formulation viscosity, fill volume, size of needle, and drug delivery time, and are compatible with standard prefilled syringes. They also include an integrated needle safety system.
While self-administered devices traditionally take a long time to develop, Ms. Righton says the development of VapourSoft is a significant advancement. “These platforms provide ready-made device designs that require only minimal customization to meet the needs of the drug formulation and the Target Product Profile (TPP),” she says. “Thanks to this development, we can expect the cost and time required to develop new combination drug products, and to provide sterile fill-finish, to significantly reduce over the next few years, enabling more injectables to benefit from self-administration.”
Considering quality when drafting the TPP for the product is also crucial to making the right choices in formulation and device development to minimize the risk of problems occurring at commercialization, she says. Including factors such as the final device and packaging can ensure that proper materials and design are selected to minimize the risk of breakage and to prevent leaching or ingress of oxygen, which can degrade the product and reduce shelf life. “By developing a product with the final storage conditions and packaging configuration in mind, it is possible to prevent breakage, leaching, and contamination from occurring in the first place,” says Vincenza Pironti, PhD, Strategic Marketing Director, Recipharm. “Adopting a Quality-by-Design mindset can help achieve this goal, as it ensures a commitment to quality, and to addresses all potential quality risks embedded in the entire development process from the beginning of the project.”
In 2020, Arcturus engaged Recipharm to support the manufacture of clinical trial supplies of Arcturus’ COVID-19 vaccine candidate in an ongoing Phase I/II clinical trial. Further, the company needed to manufacture and release more than 100,000 units of ARCT-154 mRNA vaccine finished drug product in support of clinical Phase III trial study.
When Arcturus presented its mRNA vaccine candidate to Recipharm, it was at the stage of a frozen product, a ready-to-administer sterile injectable for Phase I and II clinical trials. The inherent cryogenic logistics and storage costs associated with mRNA vaccines, as well as their intended markets (under-served populations with less access to developed healthcare infrastructures), created an additional burden for Phase III clinical trial and commercialization.
“To mitigate these challenges, Recipharm collaborated with Arcturus on the technology transfer, qualification, and cGMP manufacturing of the lyophilized product to ease the complexities of distribution and extension of vaccine shelf life,” explains Dr. Pironti. “Timelines were successfully accelerated to meet the demands of the global COVID-19 pandemic response.”
Innovation and growth in biologics have created innovation and growth in PFS, including RTU/RTF formats and polymer PFS. Sanner GMbH produces polymer prefilled syringes and accessories, as well as custom device solutions. “Polymer PFS are becoming a more viable alternative to glass syringes,” says Viola Wedl, Product Management Medtech, Sanner Group. “COC material, for example, offers a solution to breakage, and advancements in coatings are closing the performance gap compared to glass.”
Sanner carefully considers patients’ needs with regards to design and user-friendliness at the earliest stage of development. Patient and user safety is equally important. A common safety feature consists of a mechanism that withdraws the needle after injection and locks it in a safety cap. But, there are other PFS features that contribute to overall device safety, such as enlarged finger grip accessories produced in two-component injection molding. There are also special plunger rods that enable the user to rotate the rod within the syringe chamber to allow a smooth injection of all substances, regardless of viscosity.
“We developed a new concept of syringe accessories for a customer in aesthetic medicine,” she explains. “This included ergonomic and modern plunger rods, and finger rest extensions to form the prefilled syringe to a complete system. As functionality and design are equally important, we shaped finger rest enlargements with a non-slip grip leads to ensure greater safety and ease of use of the PFS. We also manufactured piston rods and finger rest enlargements using two-component injection molding in the smallest shot weights for improved grip and safety during injection. The ability to rotate the syringe barrel in the finger rest enlargement allows the syringe needle to be optimally aligned, so the syringe does not have to be applied several times.”
Societal CDMO: Laying a Foundation for More Efficient Manufacturing
Societal provides preformulation, formulation development, and fill-finish services across a range of parenteral product types, technologies, and phases of drug development. According to Robert Giannini, Vice President, Innovation, Societal CMDO, the company’s formulation development and manufacturing team has produced a naltrexone implant that provides therapeutic blood levels over the period of months for the treatment of opioid dependence; produced polymeric microparticles for extended release of a chemotherapeutic agent after intraperitoneal injection; created a non-aqueous formula of an insoluble compound, which upon dilution with saline, provides sufficient time for the product to be administered without precipitation; stabilized and manufactured clinical trial supplies of a lyophilized product for highly labile pegylated molecules and mRNA/siRNA therapeutics; and created a nanoparticulate form for an extended-release (three-month) subcutaneous injection.
He says that new manufacturing processes are being developed that are more efficient and less labor intensive. “For example, there are fundamental industry trends gaining steam that may reduce the cost of manufacturing prefilled syringes with integrated safety features,” he explains. “New materials that are stronger, lighter and more durable than traditional materials. A good example are advancements in injection molding techniques. Furthermore, the manufacturing industry is also making a concerted effort to educate healthcare professionals on the use of prefilled syringes with integrated safety features, with a particular emphasis on the benefits that these devicesprovide. Combined, we expect that these factors will play a direct role in increasing demand for the devices, and in turn help reduce needlestick injuries.”
Additionally, new manufacturing processes are being developed and implemented that allow for more efficient and less labor-intensive manufacturing and a reduced risk of product defects. “We are also seeing a focus on developing new packaging technologies that are less likely to contaminate the drug, while offering better protections against potential tampering.,” says Mr. Giannini. “This is complemented by quality control groups implementing more rigorous testing procedures and technologies to monitor the manufacturing process.”
Stevanato Group combines products, technologies, and services to create tailored solutions for pharma clients. The latest addition to the company’s syringe portfolio is the Nexa Flex™ pre-sterilized polymer syringe, available in both cyclic olefin polymer (COP) and cyclic olefin copolymer (COC) materials – complementing the Nexa® platform’s existing glass container solutions.
“Nexa Flex has an optimized silicone-oil distribution along the barrel that improves gliding performance while minimizing particles – while its 100% camera inspection guarantees consistent cosmetic quality,” says Silvia Gallina, Product Manager for the syringe platform at Stevanato Group. “Moreover, it uses a tungsten-free polymer molding process to guarantee compatibly with even the most sensitive drugs.”
To address the complex needs of new biologic drugs, Stevanato Group’s portfolio includes the Alba® prefillable syringe platform. “This solution features a cross-linked coating technology, based on standard silicone, that significantly reduces the interaction between the drug product and the container surface – a crucial development for ophthalmic drugs and highly concentrated formulations prone to silicone aggression,” says Ms. Gallina.
Another development is the growth in at-home treatment driving a renewed focus on usability and a switch from intravenous to subcutaneous drug delivery to improve the patient experience. “User-friendly and automatic delivery systems, such as autoinjectors, are becoming increasingly important to increase treatment adherence and improve the patient experience, enabling a successful transition from hospital to at-home treatment,” says Enrico Barichello, Product Manager for the syringe platform at Stevanato Group. “The rapid growth of autoinjector use requires drug products to be stable in liquid form, a staked-in needle syringe for example, can accommodate a maximum dosage volume of 2mL-2.2mL, and it is becoming more important that drug containers are well fitting and do not react with the medication to avoid functionality and delivery challenges.” For this reason, Stevanato Group introduced ready-to-use vials, cartridges, and syringes that respond to the life cycle management strategies of the industry.
Technology is key to ensuring large volumes of prefilled syringes can be distributed with consistently high-quality standards. To that end, Stevanato Group implemented technology solutions into its glass processes to ensure reliable inspection and detection of dimensional and cosmetic defects, as well as particle contamination, with 100% in-line control or in-process controls.
“Combining technology innovations on both process and product enables delivery of a high value-added system that provides superior performances in terms of mechanical resistance, functionality (smooth break loose and gliding forces, ie, inferior to 5 N), and container geometries suitable for device integration in all the critical contact parts,” says Mr. Barichello. “Additionally, a robust manufacturing process and improved controls help reduce the risk of rejection of containers, thus decreasing costly re-inspection of products.”
To further enhance the quality of its products, Stevanato Group is currently undergoing an evaluation to implement Artificial Intelligence in the glass primary packaging manufacturing processes.
Beyond the manufacturing facility, primary container traceability is critical for improving production efficiency and quality. “Glass container traceability marks each primary container with a unique identity,” explains Mr. Barichello. “This machine-readable 2D barcode code allows each container to be tracked at every manufacturing process, from forming through to filing and automated inspection. This delivers significant process and quality benefits for both the glass container producer and pharma companies.”
As part of Terumo Medical Care Solutions, the Pharmaceutical Solutions Division manufactures, supplies, and supports projects associated with its polymer-based prefillable syringes, as well as injection needles, infusion sets, and novel drug delivery devices.
One example would be an ophthalmic drug being developed in a prefilled syringe application with a customer. “There are increasing numbers of patients who require ophthalmic drug administration by intravitreal injection, triggered by the rapidly aging global population,” explains Philippe Lauwers, Technology Development Director, Terumo. “And there are still unmet challenges to designing a prefilled syringe that can safely administer ophthalmic drugs via intravitreal injection.”
For example, he says that silicone oil is deposited in the eye’s vitreous body after repeated injections and cannot be evacuated. It is also a challenge to precisely deliver a dose as low as 50 microliters, which is a typical administration volume for currently available ophthalmic drugs.
In addition to understanding the challenges of ophthalmic drug delivery so too is the importance of understanding and evaluating the potential adverse impact of primary container components on the stability of drug products. In particular, complexly-engineered biotech drug products have shown to be more prone to stability concerns when exposed to silicone oil, tungsten oxides, glue residues or high energy sterilization processes.
To address these issues, Terumo’s polymer prefillable syringes offer a full silicone oil-free container closure and eliminate the use of tungsten pins and adhesives during the production process. And, by applying steam sterilization, Terumo avoids the generation of free radicals typically associated with high energy sterilization processes which may potentially impact the stability of the sensitive drug product inside the prefilled syringe.
“We are helping our customers solve these challenges with solutions such as our proprietary silicone oil-free technology, as well as precision molded polymer prefillable syringes,” says Mr. Lauwers.
Ypsomed AG: Family of Injectors for Longer Durations, Larger Volumes
Ypsomed AG has developed a new autoinjector platform for liquid medications with volumes ranging from 1.5mL to 5.5mL, the latter of which is the latest addition to the company’s YpsoMate family of devices, and is based on established YpsoMate 2.25 Pro technology. YpsoMate 5.5 enables the self-administration of larger volume medications for treating cancer, as well as rare and autoimmune diseases.
YpsoMate 5.5 features two-step handling already proven in other YpsoMate models: Remove the cap and push on the skin. The injection process is triggered automatically. YpsoMate 5.5 is equipped with a handgrip for comfortable handling and stability during injection. A continuous visual and audible signal gives the user good control over the entire injection process.
“During product design, special focus was placed on providing optimal support for larger volumes and a longer injection duration,” explains Ian Thompson, Vice President, Account & Business Development, Ypsomed AG.
YpsoMate 5.5 also features an integrated, prefilled syringe developed in collaboration with SCHOTT. “It leverages existing standards and components to optimize processes for pharmaceutical customers and shorten time-to-market, reduce development risks, ensure suitability for sensitive drugs, and facilitate compatibility with existing filling equipment,” he says. “The result of the joint development with SCHOTT is the syriQ BioPure 5.5mL, a large-volume, prefillable syringe with integrated needle.”
Ypsomed and SCHOTT have collaborated to provide new standards for both large-volume 5.5mL staked needle syringes and 1mL ready-to-use (RTU) cartridges for the YpsoMate 5.5mL autoinjector and YpsoDose 10mL patch injector, respectively. “The 10mL YpsoDose has undergone thorough internal testing and comparative studies with pharma customers,” says Mr. Thompson. “Ypsomed is committed to the successful industrialization and commercialization of YpsoDose as a new state-of-the-art patch injector.”
YpsoDose will be supplied to initial customers for clinical trials later this year. “For pharma companies to consider and invest in patch injectors, they need to access reliable device technology and implement standard filling and final assembly processes that provide a solution that fulfils the needs of patients and healthcare providers,” he says. “Fulfilling these requirements with well-thought-out device technology will allow the patch injector market to grow significantly and become established as the third self-injection device class, complementing the maturing and expanding markets for pen injectors and autoinjectors.”
- Automation in Biopharma Industry Market Report 2023-2033, VisionGain, March 20, 2023, https://www.visiongain.com/report/automation-biopharma-industry-market-2023/.
Total Page Views: 9971